A stabilization platform that addresses some of drug delivery’s most difficult challenges
Surf Bio is a preclinical biopharmaceutical company leveraging a breakthrough next-generation surfactant to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas.
As the first application of the technology, Surf Bio is developing a novel, ultra-rapid insulin for treatment of diabetes. In parallel, Surf Bio is partnering with pharmaceutical and biotech companies to incorporate the novel stabilization platform into their proprietary products.
Launched by the founders of Bigfoot Biomedical and Mode AGC, Surf Bio was founded to commercialize a breakthrough drug stabilization technology developed in the Appel Lab at Stanford University. Commercially, the technology is designed to enable reduction of refrigeration requirements, transition from IV to subcutaneous therapy, and novel pharmaceutical formulations across a range of therapeutic areas.
Mitigation of cold chain distribution requirements and extension of shelf life
Transitioning IV clinic treatments to outpatient subcutaneous injections
Opening the door for commercialization of highly unstable therapeutics
Explore some of our recently-published therapeutics research
Surf Bio has established multiple, ongoing collaborations with leading multinational pharmaceutical companies. To date, demonstrated in-vitro and in-vivo safety and efficacy data has generated significant interest from partners to evaluate Surf Bio’s technology within their proprietary product pipelines. Proposed initial applications for the technology include increasing concentrations and reducing refrigeration dependence as well as enabling hard-to-formulate therapeutics.
Reach out to learn if Surf Bio’s technology can support your product pipeline.